The SGLT2 Inhibitor Empagliflozin Directly Binds Cardiac JNK3, Uncouples c-Jun/c-Fos Signaling, and Confers Cardioprotection in Diabetic Cardiomyopathy

Authors:

Abstract
No abstract available

This publication has 40 references indexed in Scilit: